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Background. While evidence exists to support the effectiveness of neuraminidase inhibitors (NAIs) in reducing mortality when 
given to hospitalized patients with A(H1N1)pdm09 virus infection, the impact of outpatient treatment on hospitalization has not 
been clearly established. We investigated the impact of outpatient NAI treatment on subsequent hospitalization in patients with 
A(H1N1)pdm09 virus infection.
Methods. We assembled general community and outpatient data from 9 clinical centers in different countries collected between 
January 2009 and December 2010. We standardized data from each study center to create a pooled dataset and then used mixed-ef-
fects logistic regression modeling to determine the effect of NAI treatment on hospitalization. We adjusted for NAI treatment 
propensity and preadmission antibiotic use, including “study center” as a random intercept to account for differences in baseline 
hospitalization rate between centers.
Results. We included 3376 patients with influenza A(H1N1)pdm09, of whom 3085 (91.4%) had laboratory-confirmed infection. 
Eight hundred seventy-three patients (25.8%) received outpatient or community-based NAI treatment, 928 of 2395 (38.8%) with 
available data had dyspnea or respiratory distress, and hospitalizations occurred in 1705 (50.5%). After adjustment for preadmission 
antibiotics and NAI treatment propensity, preadmission NAI treatment was associated with decreased odds of hospital admission 
compared to no NAI treatment (adjusted odds ratio, 0.24; 95% confidence interval, 0.20–0.30).
Conclusions. In a population with confirmed or suspected A(H1N1)pdm09 and at high risk of hospitalization, outpatient or 
community-based NAI treatment significantly reduced the likelihood of requiring hospital admission. These data suggest that com-
munity patients with severe influenza should receive NAI treatment.
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Neuraminidase inhibitors (NAIs) were widely used in hospi-
tals, outpatient clinics, and primary care settings during the 
influenza A(H1N1) pandemic in 2009–2010. Although licensed 
on the basis of symptom reduction, deployment in 2009–2010 
was mainly targeted toward reducing complications, hospital 
admissions, and deaths. Data from randomized trials pertain-
ing to important public health outcomes, such as reductions in 
mortality and hospital admissions, for patients with A(H1N1)
pdm09 influenza are lacking. In otherwise healthy patients 
with seasonal influenza, low case severity and low frequency of 
severe outcomes contribute to a lack of statistical power in rand-
omized studies [1–3]. Notwithstanding, summaries of observa-
tional data suggest that NAIs reduced mortality in hospitalized 
patients during the 2009–2010 pandemic [4, 5]. Likewise, a 
metaanalysis of observational data on seasonal influenza prior 
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to 2009 also suggests that NAIs given to high-risk community 
patients with influenza may reduce subsequent hospitalization 
[6]. To the best of our knowledge, similar data on hospitaliza-
tion during the 2009–2010 pandemic period are absent. We 
therefore performed a global individual participant data (IPD) 
metaanalysis to address this question.
METHODS
The PRIDE Research Consortium
Research centers participating in the Post-pandemic Review of 
anti-Influenza Drug Effectiveness (PRIDE) study were iden-
tified while conducting a metaanalysis of published studies on 
the effectiveness of NAI treatment in hospitalized patients [4]. 
A detailed description of the PRIDE study has been published 
previously [5]. In total, the PRIDE consortium obtained data on 
170 858 potentially eligible patients from 81 research centers in 
38 countries across 6 World Health Organization regions. A sub-
set of these centers provided community or outpatient data, 
which were then used for the current analysis. No data were 
provided or funded for collection by pharmaceutical companies. 
The protocol for this study was registered with the PROSPERO 
register of systematic reviews (CRD42011001273) [7].
Data Standardization, Exposure, Outcome, and Covariates
Data were available on community patients or those attending 
outpatient clinics with laboratory-confirmed or clinically diag-
nosed influenza A(H1N1)pdm09 from 9 centers (Argentina, 
Canada, France, Germany, Israel, Saudi Arabia, Singapore, 
Slovenia, and the United Kingdom). These were standardized 
using a data dictionary (Supplementary Table 1) before pooling 
for analysis. The primary outcome variable was influenza-re-
lated hospital admission as determined by case records linking 
admission to the influenza illness episode. The primary expo-
sure variable was treatment with an NAI initiated in any com-
munity or outpatient setting as compared to no NAI treatment 
in the community or outpatient setting. If data were available, 
we further distinguished early treatment (NAI started ≤2 days 
after symptom onset) vs later treatment (>2 days after symp-
tom onset). We excluded from all our analyses those patients 
who received NAI treatment in the community on the day of 
hospital admission, on the grounds that treatment would not 
have had sufficient opportunity to work in these patients. This 
exclusion also accounts for any physician decisions to prescribe 
NAIs taken after a decision to admit the patient to the hospital, 
amounting to confounding by indication. Covariates adjusted 
for in the final multivariable model were outpatient or commu-
nity-based antibiotic treatment (yes/no) and propensity score 
(by quintile) for receiving NAI treatment in the community.
Propensity Scoring
We computed propensity scores for the likelihood of commu-
nity-based NAI treatment for individual patients within each 
contributing dataset using the method described by Hirano and 
Imbens [8]. Multivariable logistic regression models developed 
to calculate propensity scores included the following covari-
ates: age, sex, presence of a comorbid condition (yes/no), and 
an indicator of disease severity (in order of preference: docu-
mented severe respiratory distress or shortness of breath). The 
resulting propensity scores were then categorized into quintiles 
for use in subsequent analyses.
Statistical Analyses
In the primary analysis, we used a mixed-effects logistic regres-
sion model to investigate the association between communi-
ty-based NAI treatment and subsequent hospital admission 
using the xtmelogit command in Stata (version 14). To account 
for differences in baseline outcome between individual datasets, 
we included individual study centers as a random intercept. We 
ran both unadjusted and adjusted models, the latter containing 
covariates for community-based antibiotic treatment and pro-
pensity scores. To allow for comparisons between the unadjusted 
and adjusted models, we included missing data as a dummy 
variable category. The C-statistic (area under the receiver oper-
ating characteristic curve) was used to assess model fit. Where 
data were available, we explored the potential impact of timing 
of NAI administration (early NAI treatment vs later NAI treat-
ment) on hospitalization. We also performed stratified analysis 
in patients with laboratory-confirmed A(H1N1)pdm09 influ-
enza and adults (aged ≥16 years) and children.
Furthermore, we carried out an additional analysis restricted 
to patients with high-risk conditions. Patients were classified as 
having a high-risk condition if they had at least 1 chronic illness 
recorded that would trigger seasonal influenza vaccination [9] 
or were aged ≥65 years.
Results from our mixed-effects logistic regression models are 
presented as odds ratios (ORs) with 95% confidence intervals 
(95% CIs).
RESULTS
We received outpatient data on 130 077 patients with clinically 
or laboratory-confirmed influenza from 25 centers. However, 16 
centers (n = 125 049 patients) offered surveillance data that did 
not contain clinical data on either NAI use or subsequent hospi-
talization status. Therefore, the final study population comprised 
3376 patients from 9 study centers (Figure 1). Data from 7 of the 9 
included study centers (n = 1183 patients) came from outpatient 
(ambulatory care) clinics attached to hospitals. Of the remaining 
2 study centers, 1 provided community surveillance data collected 
by a local Ministry of Health (n = 1762) and the other provided 
data from primary care (n = 431). Three of the 9 included centers 
(Canada, Germany, and Israel; total n = 535) were from pediat-
ric outpatient clinics and comprised entirely of patients aged <18 
years. Patients from the German study center were particularly 
young with a median age of 1.4 years (Supplementary Table 3).
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Of 3376 patients in our pooled dataset, 3085 (91.4%) had 
laboratory-confirmed A(H1N1)pdm09 infection; 1747 (51.8%) 
were children (<16 years) and 67 (2.0%) were aged >64 years. 
Overall, 1705 (50.1%) were admitted to the hospital and 928 
(928/2395; 38.7%) had clinically observed shortness of breath 
or respiratory distress as a marker of severity. Where data were 
available (n = 473), the median interval between date of symp-
tom onset and date of NAI treatment initiation was 1 day (inter-
quartile range [IQR], 0–3) for the whole study population, 1 day 
(IQR, 0–2) for nonhospitalized patients, and 1 day (IQR, 0–4) 
for hospitalized patients. Of the hospitalized patients, where cal-
culable (n = 1363), the median interval between date of symp-
tom onset and date of hospital admission was 2 days (IQR, 1–3). 
General characteristics of the study population are presented in 
Table  1. About one half (50.1%) of the cohort was eventually 
admitted to the hospital, and 38.8% had 1 or more indications 
of severe respiratory illness as denoted by observed shortness of 
breath or respiratory distress. In addition, fewer than 2% of the 
cohort were elderly and about 72% had no recorded comorbid 
conditions, suggesting that most patients were young and previ-
ously healthy. Indeed, 51.8% were children and 37.1% of women 
aged 15–44  years were pregnant, reflecting the inclusion of 1 
obstetric clinic (n = 81) within the data.
Of the 1705 patients who were hospitalized, we had data 
on the subsequent course in 1433 patients. Of these hospital-
ized patients, 1155 (80.6%) were treated with NAIs in-hos-
pital, 147 patients (10.3%) were subsequently admitted to 
critical care facilities (of which 119 [80.9%] treated, 28 [19.1%] 
untreated), and 14 patients (1%) died (13 [92.9%] treated, 1 
[7.1%] untreated). In a smaller subgroup of 1392 patients on 
whom we had data relating to pneumonia, 215 (15.5%) were 
found to have clinical signs of pneumonia, with radiographic 
confirmation of pneumonia in 101 (7.3%) patients (64 [63.4%] 
treated, 37 [36.6%] untreated). Further, we had data on length 
Figure 1. Study flow diagram. Abbreviation: NAI, neuraminidase inhibitor.
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of subsequent hospital stay in a smaller subgroup of 522 patients 
where the median length of stay was 3 days (IQR, 2–5; median, 
3 days [IQR, 2–5] in treated and median, 2 days [IQR, 1.5–5] 
untreated). Of the 1647 patients who were excluded from the 
analyses because they were hospitalized on the same day as NAI 
treatment initiation, 116 (7%) were admitted to critical care 
facilities and 23 (1.4%) died. In 1595 of these patients on whom 
we had pneumonia data, 154 (9.7%) were found to have had 
clinical signs of pneumonia; in 31 (1.9%) of these patients the 
pneumonia was radiologically confirmed. The median length of 
hospital stay in an even smaller subgroup (n = 186 where data 
were available) was found to be 3 days (IQR, 2–5).
In patients with laboratory-confirmed or clinically diag-
nosed A(H1N1)pdm09 influenza, after adjustment for com-
munity-based antibiotic treatment and propensity score, 
the likelihood of hospital admission in patients with outpa-
tient or community-based NAI treatment was 0.24 (95% CI, 
0.20–0.30) when compared to no NAI treatment in the com-
munity (Table 2). A C-statistic of 0.813 (95% CI, 0.799–0.827) 
suggested that the predictive performance of our model was 
acceptable.
When restricted to laboratory-confirmed A(H1N1)pdm09 
patients, the estimate was very similar to the estimate for the 
overall study population (Table  2). NAI treatment, when 
Table 1. General Characteristics of the Study Population 
Variable
All Patients
(n = 3376)
Nonhospitalized
(n = 1671)
Hospitalized
(n = 1705)
Number of male cases 1712 (50.71) 859 (51.41) 853 (50.03)
Age, median (interquartile range) in years (n = 3253) 14 (4.95 to 27.88) 14 (6.24 to 27) 15 (3.85 to 28.47)
Population group (no. of persons)
 Adults (≥16 years) 1506 (44.61) 730 (43.69) 776 (45.51)
 Children (<16 years) 1747 (51.75) 879 (52.60) 868 (50.91)
 Aged ≥65 years 67 (1.98) 22 (1.32) 45 (2.63)
 Pregnant womena (n = 741) 237/639 (37.09) 121/278 (43.53) 116/361 (32.13)
Country
 Argentina 17 (0.50) 13 (0.78) 4 (0.23)
 Canada 148 (4.34) 113 (6.76) 35 (2.05)
 France 81 (2.40) 55 (3.29) 26 (1.52)
 Germany 314 (9.29) 161 (9.63) 153 (8.95)
 Israel 73 (2.16) 36 (2.15) 37 (2.16)
 Saudi Arabia 1762 (52.11) 613 (36.68) 1,149 (67.19)
 Singapore 490 (14.49) 242 (14.48) 248 (14.50)
 Slovenia 60 (1.77) 24 (1.44) 36 (2.11)
 United Kingdom 431 (12.77) 414 (24.78) 17 (1.00)
A(H1N1)pdm09 diagnosis
 Laboratory confirmed 3,085 (91.38) 1,522 (91.08) 1,563 (91.67)
 Clinically diagnosed 291 (8.61) 149 (8.92) 142 (8.33)
Severe disease (n = 2395) (severe respiratory distress or  
shortness of breath at presentation)
928/2395 (38.75) 321/991 (32.39) 607/1404 (43.23)
Comorbidity
Any comorbidity (n = 2945) 824/2945 (27.98) 302/1,257 (24.03) 522/1688 (30.92)
 Asthma (n = 1172) 214/1172 (18.26) 91/634 (14.35) 123/538 (22.86)
 Chronic obstructive pulmonary disease (n = 902) 120/902 (13.30) 38/471 (8.07) 82/431 (19.03)
 Other chronic lung disease (n = 2257) 290/2257 (12.85) 98/871 (11.25) 192/1386 (13.85)
 Heart disease (n = 614) 20/614 (3.26) 4/294 (1.36) 16/320 (5.00)
 Renal disease (n = 2299) 92/2299 (4.00) 40/879 (4.55) 52/1420 (3.66)
 Liver disease (n = 541) 11/541 (2.03) 5/258 (1.94) 6/283 (2.12)
 Cerebrovascular disease (n = 490) 7/490 (1.43) 1/242 (0.41) 6/248 (2.42)
 Neurological disease (n = 2448) 57/2488 (2.33) 9/963 (0.93) 48/1485 (3.23)
 Diabetes (n = 2449) 135/2449 (5.51) 47/964 (4.88) 88/1485 (5.93)
 Immunosuppression (n = 2390) 97/2390 (4.06) 36/918 (3.92) 61/1472 (4.14)
Community/outpatient NAI treatment
 Any NAI treatment 873 (25.82) 653 (39.08) 220 (12.90)
 Oseltamivir b (n = 2945) 590 /2,94 (20.03) 385/1257 (30.63) 205/1688 (12.14)
Study size n = 3376. Percentages presented are column percentages unless other denominators are specified.
Abbreviation: NAI, neuraminidase inhibitor.
aProportions were calculated as a percentage of pregnant patients among female patients of reproductive age; the broader age range was selected in preference to the World Health 
Organization definition (15–44 years) after consultation with data contributors to reflect the actual fertility experience of the sample. This includes data from an obstetric outpatients clinic 
(n = 81).
bWhere it was explicitly stated that the NAI administered was oseltamivir.
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compared to no treatment, was associated with reduced odds 
of hospitalization in both children (adjusted OR, 0.25; 95% CI, 
0.18–0.34) and adults (adjusted OR, 0.26; 95% CI, 0.19–0.35). 
In the subgroup of 473 patients in whom data on the inter-
val between symptom onset and start of NAI treatment were 
available, early NAI treatment was associated with an adjusted 
OR of 0.44 (95% CI, 0.23–0.86) when compared to later NAI 
treatment.
In the pooled dataset, 1019 patients (30.1%) were recorded 
to have at least 1 high-risk condition. In this subpopulation of 
higher-risk patients, we also observed a reduction in the odds 
of hospital admission (OR, 0.27; 95% CI, 0.19–0.38) in those 
treated with NAIs in the community compared with no NAI 
treatment. Full results of the sensitivity and stratified analyses 
are summarized in Table 2.
The hospital admission rate varied widely among each of the 
9 included study centers, ranging from 3.94% to 69.3%. To sepa-
rate any effects that hospital admission rates among centers may 
have had on the association between NAIs and hospitalization, 
we did a post hoc stratified analysis by median hospitalization 
rate (50.6%). After adjusting for community-based antibiotic 
treatment and propensity score, the pooled OR for the associa-
tion between NAI treatment and subsequent hospitalization in 
study centers with a hospital admission rate <50.6% (n = 991) was 
1.00 (95% CI, 0.61–1.64), whereas in centers where the admission 
rate was >50.6% (n = 2385), the OR was 0.17 (95% CI, 0.14–0.22).
DISCUSSION
In this study, we assembled data from a large cohort of com-
munity-based patients who had pandemic influenza in 2009–
2010, of whom 91% had laboratory confirmation of influenza 
A(H1N1)pdm09 infection. The demographic and clinical find-
ings (Table 1) reveal that most patients were young and previ-
ously healthy, yet with relatively severe influenza (indicated by 
the presence of either documented severe respiratory distress or 
shortness of breath at presentation). As such, we recognize that 
our results are not generalizable to a wider range of communi-
ty-based patients with mild pandemic influenza and may not be 
generalizable to the elderly.
Our main findings (Table 2) suggest that NAI treatment in the 
community for patients with severe pandemic influenza substan-
tially reduced the likelihood of hospital admission due to influenza 
A(H1N1)pdm09. In a pandemic context, individuals generally 
have little or no preexisting cross-reactive immunity to the infect-
ing virus; therefore, effect size might be lower for seasonal (inter-
pandemic) influenza, and our findings should be interpreted with 
more caution in that context. In a sensitivity analysis restricted to 
patients with laboratory-confirmed A(H1N1)pdm09, this finding 
was unaltered; and in patients with underlying at-risk conditions, 
the risk reduction was greater. A limitation of our analysis is that 
we did not have data on body mass index and therefore could not 
include obesity as a high-risk condition.
We also explored potential differences in effect size between 
adults and children and found that the effect of NAIs in reduc-
ing the likelihood of hospital admission was maintained and 
broadly consistent in both age groups. These findings contrast 
with our previous analysis of mortality data, in which we failed 
to demonstrate significantly reduced mortality in hospitalized 
children treated with NAIs [5]. This discrepancy is potentially 
explained by the relatively high attack [10] and hospitalization 
rates in children with A(H1N1)pdm09 [11] compared with a 
relatively low case fatality rate [12] but could also relate to sta-
tistical underpowering in the mortality study [5].
A question of considerable clinical relevance relates to the 
timing of antiviral treatment in relation to the magnitude of 
benefit obtained, especially since data already exist to suggest 
that symptom alleviation and mortality reduction are both 
diminished by delayed treatment [5, 13]. We were able to per-
form a sensitivity analysis on 473 NAI-treated patients in whom 
we had specific data on the timing of symptom onset and anti-
viral treatment. This revealed that earlier treatment (within 48 
hours of symptom onset) was significantly more beneficial than 
later treatment.
Table 2. Association Between Neuraminidase Inhibitor Administration and Hospital Admission
Population
Unadjusted Analysis Adjusted Analysisa
Unadjusted OR (95% CI) P Value Adjusted OR (95% CI) P Value
Patients with laboratory-confirmed or clinically  
diagnosed A(H1N1)pdm09 influenza (n = 3376)
0.23 (0.19 to 0.28) <.001 0.24 (0.20 to 0.30) <.001
Patients with laboratory-confirmed A(H1N1)pdm09  
influenza (n = 3085)
0.23 (0.19 to 0.28) <.001 0.24 (0.19 to 0.29) <.001
Adults (aged ≥16 years) (n = 1506) 0.26 (0.19 to 0.35) <.001 0.26 (0.19 to 0.35) <.001
Children (aged <16 years) (n = 1747) 0.22 (0.17 to 0.30) <.001 0.25 (0.18 to 0.34) <.001
Patients with at least 1 high-risk condition (n = 1019) 0.26 (0.19 to 0.37) <.001 0.27 (0.19 to 0.38) <.001
Early neuraminidase inhibitor treatment (≤2 days after onset) vs  
later (>2 days) in patients with laboratory-confirmed or clinically  
diagnosed A(H1N1)pdm09 influenza (n = 473)
0.51 (0.28 to 0.93) .031 0.44 (0.23 to 0.86) .016
aAdjusted for treatment propensity (by quintile) and community-based antibiotic use.
Abbreviations: CI, confidence interval; OR, odds ratio.
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Because the dataset contained so few elderly patients, perhaps 
reflecting the low incidence of A(H1N1)pdm09 infection in the 
elderly [14, 15], we were unable to cast any further light on the 
effectiveness of NAIs in this particular subgroup of patients.
Although smaller than our previous IPD analysis that 
focused on mortality reduction in hospitalized patients [5], 
one strength of this study is the relatively large number of 
patients included from 9 geographically diverse clinical centers. 
Although we were unable to adjust specifically for disease sever-
ity in our multilevel models because of the heterogeneity of 
severity measures used across individual datasets, we neverthe-
less included physician-recorded breathlessness and severe res-
piratory distress when deriving propensity scores. However, we 
acknowledge that confounding by indication [16] may still be 
present. If it is, we surmise that physicians may have been more 
likely to treat severe cases than milder ones or to treat putative 
at-risk groups such as pregnant women with NAIs. Therefore, 
the treated group would have a higher underlying likelihood of 
being admitted to the hospital; this in turn would produce a bias 
in the analysis, tending toward underestimation of any treat-
ment effect. Likewise, we recognize that some NAI treatment 
may have been given immediately prior to hospital admission 
when there was no practical window in which an antiviral drug 
could have had time to work or perhaps even when the physi-
cian had already decided that the patient needed to be admitted. 
Therefore, we think there is sound clinical rationale for exclud-
ing patients in whom NAI treatment was initiated on the day of 
hospital admission.
Another potential limitation of our propensity scoring 
approach is that we lacked data on vaccination, albeit knowl-
edge of vaccination status might be associated with physi-
cians’ decisions to prescribe NAIs and to hospitalize patients. 
To explore this further, we determined that patients whose 
illness onset was on or before 15 October 2009 could not have 
been vaccinated due to nonavailability prior to this date. Even 
if they had been vaccinated, they would not have had time to 
seroconvert. We subsequently performed a stratified analysis 
around this date by dividing the overall pooled dataset into 
“early pandemic” and “later pandemic.” We had onset dates in 
2175 patients of whom 903 were on or before 15 October 2009. 
The adjusted ORs (95% CIs) in both groups were very similar 
(early pandemic group, 0.12 (0.06–0.24) and late pandemic 
group, 0.11 (0.07–0.18)]. On this basis, we believe that vaccina-
tion is unlikely to have been a major confounder in our study. 
Other residual confounding is nevertheless possible as these are 
observational data.
Two obvious drawbacks in our data are the overall high rate 
of hospitalization in the cohort studied, which limits gener-
alizability to patients at high risk of hospitalization, and the 
substantial variability between hospitalization rates across indi-
vidual centers, ranging from 4% to 70%. The dataset with the 
lowest hospitalization rate was from a surveillance system in 
the United Kingdom where a national policy was in place for 
2009–2010 to offer NAI treatment to all patients with clinically 
apparent influenza, irrespective of severity. Stratifying the anal-
ysis around median hospitalization rate revealed no effect of 
NAIs in centers below the median but revealed a strong positive 
effect in centers above the median. We surmise that these data 
confirm the beneficial effect of NAIs (beyond symptom relief) 
in patients who are severely unwell and at high risk of hospital-
ization vs those with milder illness.
To our knowledge, this is the first individual participant 
data metaanalysis to investigate the association between pre-
admission NAI antiviral use and hospitalization relating to the 
2009–2010 influenza pandemic. As such, these data have poten-
tial importance for future pandemic stockpiling and treatment 
policies and may be of relevance to seasonal epidemics, espe-
cially for community patients with relatively severe influenza 
and those with underlying comorbidities. We note that our 
point estimates of treatment effectiveness are somewhat higher 
than the 25% reduction in hospitalization for the treatment of 
seasonal influenza previously reported by Hsu and colleagues 
[6]. However, the disparity in effect size might be explained 
by the fact that the 4 studies [17] metaanalyzed by Hsu et  al 
included patients with generally milder influenza than in the 
present study. In addition, 3 of these 4 studies were based on 
diagnoses of influenza-like illness (ILI) without laboratory 
confirmation and therefore were highly vulnerable to misclas-
sification bias. An earlier pooled analysis of clinical trial data 
from patients with laboratory-confirmed seasonal influenza 
also showed a 59% reduction in hospitalization [18]. This was 
confirmed in recent IPD analysis of seasonal influenza patients 
that reported a risk reduction of 63% in treated patients (inten-
tion-to-treat infected population) [19], which is somewhat 
similar to our own data. Another study not included in Hsu’s 
metaanalysis also suggested a 29% reduction in hospitalization 
associated with oseltamivir but was again based on diagnoses of 
ILI without laboratory confirmation [20]. A recent study from 
British Columbia, based on clinically diagnosed cases of pan-
demic influenza A(H1N1)pdm09, also noted 16% effectiveness 
of NAIs in reducing hospitalization [21]; however, the hospi-
talization rate in this cohort was 0.6%, suggesting cases were 
comparatively very mild. We therefore recognize that our find-
ings reflect the experience of NAI use in a cohort of community 
patients at high risk of hospitalization. In addition, we noted 
higher effectiveness in patients with 1 or more comorbidities 
that would have placed them in a target group for annual sea-
sonal influenza vaccination.
Placed in the context of the limited previous work on this 
subject, our findings suggest that the greatest benefit from 
community use of NAIs is likely to be achieved by targeting 
individuals for treatment who have clinically suspected or 
proven influenza and who are also in a recognized at-risk group 
or clinically assessed to have severe influenza (irrespective 
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of comorbid status). In these 2 groups of patients, substantial 
reductions in the likelihood of hospitalization can be achieved, 
especially if treatment is commenced within 48 hours of symp-
tom onset. Our data support current advice on NAI treatment 
given by major public health agencies [22, 23] and the find-
ings of a recent independent report from the UK Academy of 
Medical Sciences and the Wellcome Trust, which recommend 
against use of NAIs in the community for the treatment of mild 
influenza, but advise that patients with severe influenza should 
be treated as soon as possible [24].
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